British American Tobacco p.l.c.

What they do

British American Tobacco manufactures and sells combustible cigarettes, tobacco heating products, vapour products, and oral nicotine products, including modern oral (snus and nicotine pouches). The company operates through three reportable segments: U.S., Americas & Europe, and Asia-Pacific, Middle East & Africa. Its portfolio includes global cigarette brands such as Camel and Newport, and it also markets a range of reduced-risk products.

Revenue drivers

• U.S. segment — The U.S. segment generates revenue from the sale of combustible cigarettes and other tobacco products in the United States, including brands such as Camel and Newport, and is a major contributor to group revenue and profit.
• Americas & Europe segment — This segment earns revenue from the sale of combustible and reduced-risk products across markets in the Americas (excluding the U.S.) and Europe, including vapour and oral nicotine products.
• Asia-Pacific, Middle East & Africa segment — This segment derives revenue from the sale of tobacco and nicotine products across markets in Asia-Pacific, the Middle East, and Africa, including combustible cigarettes and tobacco heating products.
• Reduced-risk products — The company markets vapour, tobacco heating, and modern oral products as part of its portfolio, though the filings do not break out separate financial results for these product categories.

Recent performance

The provided excerpts do not include specific revenue, profit, or volume figures for the latest reported period. The filings indicate the company operates through three reportable segments and references constant rate and translation exchange impacts, but no performance metrics are disclosed in the provided text. As a result, no meaningful summary of recent financial performance can be provided from the available information.

Strategy

The company's stated direction, investments, and priorities are not detailed in the provided excerpts. The filings reference segment reporting and constant currency adjustments, but no strategic initiatives or capital allocation plans are described in the available text. Therefore, no summary of strategy can be provided from the source material.

Risks

• Litigation risk — The company faces tobacco-related litigation, including a Canadian settlement involving an upfront payment, as referenced in the filings.
• Regulatory risk — Tobacco and nicotine products are subject to extensive regulation, which can affect product sales, marketing, and taxation.
• Foreign exchange risk — As a global company, BAT's reported results are affected by translation exchange movements, as indicated by segment reporting in constant rates.
• Intangible asset impairment risk — The filings mention brand names and computer software with finite useful lives, indicating potential impairment risk if performance declines.

Outlook

The provided excerpts do not include management's forward-looking statements or guidance. No outlook can be provided from the available information.